6505--Trastuzumab and Biosimilars (VA-25-00052526)

The Department of Veterans Affairs National Acquisition Center is seeking to procure Trastuzumab and Biosimilars through solicitation number 36E79725R0038. This pharmaceutical contract encompasses two line items: Trastuzumab injection 150mg/Vial with an estimated annual quantity of 10,297 vials and 420mg/Vial with an estimated annual quantity of 1,426 vials. The contract structure includes a base year and four one-year option periods, with one aggregate award to be made for both line items. Eligible offerors must demonstrate FDA approval, current Good Manufacturing Practices (cGMP) compliance, and provide a unique 11-digit NDC number for each offered drug, along with a Letter of Commitment from the manufacturer if the offeror is not the manufacturer. Originally due July 8, 2025, the proposal submission deadline has been extended to July 15, 2025, at 2:30 PM CDT. The solicitation requires pricing submissions that include a 0.5% Cost Recovery Fee for the base year and all four option years.

This procurement is designated as a small business set-aside with a size standard of 1,300 employees under NAICS code 325412 for Pharmaceutical Preparation Manufacturing. The contract will serve multiple federal agencies including the Department of Veterans Affairs, Department of Defense, Indian Health Service, Bureau of Prisons, and the Federal Health Care Center. Distribution will be handled through Pharmaceutical Prime Vendors such as McKesson Corporation and Cencora. The place of performance is located in Hines, Illinois, with the VA National Acquisition Center managing the procurement process. Contract Specialist Anthony DiCrescenzo serves as the primary point of contact and can be reached at Anthony.DiCrescenzo@va.gov or 877-634-3739. The anticipated contract award and effective date is scheduled for June 23, 2025, following the evaluation of submitted proposals.